In a meta-analysis of multiple published cohorts, pooled mean IL-6 plasma levels for COVID-19 patients (n = 1,245) were significantly lower compared to other critical conditions, including chimeric antigen receptor (CAR)-T cell-induced cytokine release syndrome (100-fold difference, n = 72), hyperinflammatory ARDS (50-fold difference, n = 868), sepsis (30-fold difference, n = 5,320), and hypoinflammatory ARDS (5-fold difference, n = 1,899)14. The gene discussed is IL6; the disease is COVID-19.